From this Monday, family doctors in England are able, for the first time, to prescribe the weight-loss drug Mounjaro on the NHS, a step that quietly widens a path that until now ran only through specialist services. It opens first to a narrow group, those with a very high body mass index and several obesity-linked illnesses, and is expected to reach around 220,000 people over three years. Yet it arrives into a system already stretched thin, where general practice carries heavy workloads and where many who need help will still reach for private prescriptions, leaving the larger question of prev
NHS Opens Weight-Loss Jabs to GP Prescribing in England, Starting With 220,000 Patients
Not a silver bullet
Mark
So what actually changes on Monday?
Mimi
GPs in England can prescribe Mounjaro themselves. Before, patients had to go through a special weight loss service.
Mark
Who qualifies?
Mimi
In year one, people with a BMI over 40 and at least four other obesity-linked conditions, like type 2 diabetes, high blood pressure, heart disease or sleep apnoea.
Luke
And the 220,000 figure, is that a count of who will get it?
Mimi
It's what's expected over three years for people with the greatest need. It's a projection, not a tally.
Mark
Why are GPs uneasy?
Mimi
Workload and training. The Royal College of GPs says practices are already stretched and many doctors worry about starting and managing these treatments properly.
Luke
Worth saying that's the college's account of what GPs feel. The piece doesn't give a survey number.
Mark
Pharmacists raised something different, didn't they?
Mimi
Supply. Olivier Picard expects prescriptions to climb quickly and says the NHS won't meet demand straight away, so people will keep buying privately.
Luke
That's his expectation. Nothing here shows how big the shortfall will be, or whether supply will actually run short.
Mark
Anything beyond the drug itself?
Mimi
Prof Hawthorne said it's no silver bullet and that prevention matters, so fewer people need treatment later.
Il Polso
- A new NHS route to Mounjaro opens from Monday, but only for patients with a BMI above 40 and at least four obesity-linked conditions.
- Family doctor leaders warn that GPs are already buckling under workload and lack the training needed to start these treatments safely.
- The Royal College of GPs insists the drugs are no silver bullet and that prevention must not be sidelined by a medical quick fix.
- Pharmacy leaders expect demand to far outrun NHS supply, pushing many patients back toward private purchases.
- The rollout's real test now lies in whether practices can absorb the extra work and whether tirzepatide supply holds through the three-year plan.
From this Monday, family doctors in England are able, for the first time, to prescribe the weight-loss drug Mounjaro on the NHS, a step that quietly widens a path that until now ran only through specialist services. It opens first to a narrow group, those with a very high body mass index and several obesity-linked illnesses, and is expected to reach around 220,000 people over three years. Yet it arrives into a system already stretched thin, where general practice carries heavy workloads and where many who need help will still reach for private prescriptions, leaving the larger question of prevention unanswered.
From Monday, a family doctor in England can write a prescription for Mounjaro on the NHS. Until now, patients could only reach the weight-loss drug through a specialist weight loss service, so this change opens a new door, though a narrow one for now.
The drug, tirzepatide, made by Eli Lilly, lowers blood sugar and slows digestion. Around 220,000 people judged to have the greatest need are expected to receive it over the next three years. In the first year, eligibility requires a body mass index above 40 and at least four linked health problems, such as type 2 diabetes, high blood pressure, heart disease or sleep apnoea. The rollout follows guidance from the National Institute for Health and Care Excellence.
Demand is not new. Roughly 1.5 million people in the UK already take weight-loss drugs, through specialist services or private prescription. The Royal College of GPs welcomes the potential benefits but warns that many GPs fear the added workload and lack training, while practices already face intense pressure. Its chair, Prof Kamila Hawthorne, also cautions against calling the drugs a silver bullet, arguing that prevention must stay central so fewer people need medical help later.
Pharmacists see the pressure differently. Olivier Picard of the National Pharmacy Association says demand is rising sharply and that prescriptions will climb quickly. He is candid that NHS provision will not meet demand at once, so many people will likely keep buying the drug privately. How general practice copes and whether supply holds are the questions to watch as the three-year rollout begins.
From Monday, a family doctor in England can write a prescription for Mounjaro on the NHS. Until now, patients could only get the weight-loss drug through a specialist weight loss service. The change opens a new route to treatment, and it starts with a narrow group.
The drug is tirzepatide, made by Eli Lilly and sold as Mounjaro. It lowers blood sugar levels and slows the speed at which food is digested. About 220,000 people judged to have the "greatest need" are expected to receive it on the NHS over the next three years.
Eligibility in the first year is tightly drawn. Patients must have a body mass index above 40 and at least four other health problems linked to obesity. The source names type 2 diabetes, high blood pressure, heart disease and obstructive sleep apnoea as examples of those conditions.
The NHS is moving to put into practice guidance from the National Institute for Health and Care Excellence, which is the basis for the wider availability of tirzepatide. The NHS is not starting from zero demand. Estimates suggest about 1.5 million people in the UK already take weight-loss drugs, either through specialist weight loss services or on private prescription.
The Royal College of GPs has welcomed the potential benefits but not the lack of preparation it sees. Its chair, Prof Kamila Hawthorne, said many GPs are worried about what the rollout means for their workload and for the training needed to start and manage these treatments properly. She said practices are already working under intense workload and workforce pressures, and that this must be factored in if the rollout is to be delivered safely.
Hawthorne also cautioned against treating the drugs as a "silver bullet". For patients who struggle to lose weight and meet every clinical criterion, she said, the medications hold real promise. But she argued that the health service also needs to focus on prevention, stopping people becoming overweight so they do not need a medical intervention later.
Pharmacists are looking at a different pressure point: supply. Olivier Picard, chair of the National Pharmacy Association, said demand for the jabs continues to rise sharply. As tirzepatide becomes prescribable to more patients, he said, prescription volumes should increase rapidly. Experts in pharmacy have also warned that the drug's supply could come under strain.
Picard was blunt about the limits of the NHS offer. Provision will not meet demand straight away, he said, so he expects many people to keep seeking the drug privately from a pharmacy. How general practice absorbs the extra work, and whether supply holds up, are the things to watch as the three-year rollout begins.
Citazioni salienti
Weight-loss medications must not be seen as a 'silver bullet', and the focus should also be on prevention.— Prof Kamila Hawthorne, chair, Royal College of GPs
NHS provision won't meet demand straight away, so many people will continue seeking it privately from a pharmacy.— Olivier Picard, chair, National Pharmacy Association
Vuoi la storia completa?
Leggi l'originale su The Guardian ↗
Health & Medicine